News

Corvus Pharmaceuticals Announces Initiation of Phase 1b Clinical Trial of Soquelitinib for Patients with Hidradenitis Suppurativa

Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biologySOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa. “The initiation of our Phase 1b hidrade

Yahoo·16:05CRVS▲+0.8%

Corvus Pharmaceuticals Starts Enrollment In Its Phase 1b Clinical Study Of Soquelitinib To Treat Hidradenitis Suppurativa

Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with

Benzinga·12:07CRVS▲+0.8%

Corvus Pharmaceuticals (CRVS) Faces A Valuation Test, Is The Upside Already Priced In?

Corvus Pharmaceuticals (CRVS) has drawn fresh attention after recent trading left the biotech down about 19% over the past month and 13% over the past 3 months from a US$11.80 close. That recent slide sits against a much stronger ride for Corvus Pharmaceuticals, with the share price return still up 61.2% year to date and the 1 year total shareholder return at 78.52%, while the 3 year total shareholder return is very large at roughly 7x. This indicates strong long term momentum even as short...

Yahoo·10:09CRVS▲+0.8%

Corvus: Evaluating Soquelitinib's Science, Market Reach, And Fair Value

SeekingAlpha·06:26CRVS▲+0.8%

Corvus: Strong Buy Soquelitinib Q1 2027 Interim Futility Analysis And AD Drug Advancement

Corvus Pharma (CRVS) Strong Buy: soquelitinib PTCL & atopic dermatitis catalysts, key 2027 readouts, $215M cash to Q2 2028—read now.

SeekingAlpha·23:51CRVS▲+0.8%